B
VNDA icon

Bailard’s Vanda Pharmaceuticals VNDA Stock Holding History

Bailard’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,800
Closed -$116K – 855
2026
Q1 		$116K Buy
+16,800
New +$130K ﹤0.01% 719
2025
Q4 		– Sell
-26,169
Closed -$131K – 885
2025
Q3 		$131K Buy
26,169
+69
+0.3% +$319 ﹤0.01% 752
2025
Q2 		$123K Buy
26,100
+3,631
+16% +$15.9K ﹤0.01% 735
2025
Q1 		$103K Buy
+22,469
New +$105K ﹤0.01% 718
2024
Q1 		– Sell
-26,300
Closed -$111K – 824
2023
Q4 		$111K Buy
+26,300
New +$106K ﹤0.01% 684

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bailard's VNDA Position: Q2 2026 in Review

Bailard sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 16,800 shares — an estimated $116K sold.

Bailard first reported a position in VNDA in Q4 2023 and held it in 5 quarters. The position peaked at $131K in Q3 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Bailard reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bailard sold 16,800 Vanda Pharmaceuticals shares in Q2 2026, an estimated $116K.
  • Bailard first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Bailard's Vanda Pharmaceuticals position peaked at $131K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.